Leo Pharma

American Skin Association Announces New Board Member Eugene A. Bauer, MD

Wednesday, September 15, 2021 - 4:36pm

NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.

Key Points: 
  • NEW YORK, Sept. 15, 2021 /PRNewswire/ -- American Skin Association (ASA) today announced that Eugene Bauer, MD, will join its Board of Directors.
  • He is immediate past co-founder, Chief Medical Officer, and member of the Board of Directors of Dermira, Inc., a biotechnology company recently acquired by Eli Lilly and Company.
  • "We are proud to announce the addition of Dr. Eugene Bauer to ASA's Board of Directors.
  • Prior to that, he was co-founder and member of the Board of Directors at Connetics, a commercial dermatology company.

Global Patient-Led Effort To Measure And Improve Eczema Care Launched

Tuesday, September 14, 2021 - 12:00pm

The GPIIEC will collect and analyze data from primary surveys and secondary data across the eight countries to create a comparative global dashboard of eczema care. The joint effort will lead to data-driven insights about each country's areas of strength and weakness in meeting the needs of people who live with eczema -- and result in policy recommendations for addressing them.

Key Points: 
  • SANTA BARBARA, Calif., Sept. 14, 2021 /PRNewswire/ --Eleven patient organizations from eight countries have joined together to launch the Global Patient Initiative to Improve Eczema Care (GPIIEC) on World Eczema Day.
  • The GPIIEC will collect and analyze data from primary surveys and secondary data across the eight countries to create a comparative global dashboard of eczema care.
  • The global initiative is supported with funding from LEO Pharma, a leader in medical dermatology dedicated to changing the standards of care for people with skin diseases.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Global Patient-Led Effort To Measure And Improve Eczema Care Launched

Tuesday, September 14, 2021 - 7:00am

The GPIIEC will collect and analyze data from primary surveys and secondary data across the eight countries to create a comparative global dashboard of eczema care. The joint effort will lead to data-driven insights about each country's areas of strength and weakness in meeting the needs of people who live with eczema -- and result in policy recommendations for addressing them.

Key Points: 
  • SANTA BARBARA, Calif., Sept. 14, 2021 /PRNewswire/ --Eleven patient organizations from eight countries have joined together to launch the Global Patient Initiative to Improve Eczema Care (GPIIEC) on World Eczema Day.
  • The GPIIEC will collect and analyze data from primary surveys and secondary data across the eight countries to create a comparative global dashboard of eczema care.
  • The global initiative is supported with funding from LEO Pharma, a leader in medical dermatology dedicated to changing the standards of care for people with skin diseases.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries.

Drug Delivery Devices Global Markets Report 2021: Oral, Injectable, Topical, Ocular, Pulmonary, Nasal, Transmusocal, Implantables - ResearchAndMarkets.com

Friday, August 6, 2021 - 1:50pm

The "Drug Delivery Devices Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Delivery Devices Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Drug Delivery Devices Global Market Report 2021 covers this critical market and the impact on it from the COVID-19 virus.
  • The regulatory changes related to medical devices is expected to restraint the growth of drug delivery devices market.
  • Global Drug Delivery Devices Market, Segmentation By Route Of Administration, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

Tuesday, May 11, 2021 - 12:30pm

In addition, we are preparing for our Phase 2b trial for ASLAN004, which we expect to initiate in the second half of 2021.

Key Points: 
  • In addition, we are preparing for our Phase 2b trial for ASLAN004, which we expect to initiate in the second half of 2021.
  • Prior to joining ASLAN, Dr Veverka was Senior Medical Director and Medical Head for the Innovative Portfolio at LEO Pharma, a leader in global dermatology.
  • Mr Suttner brings more than 20 years in clinical operations and R&D, including more than 8 years in dermatology.
  • Following the financing activities in the first quarter of 2021, the number of ADSs outstanding on 31 March 2021 was 69.5 million (representing 347.6 million ordinary shares).

Valeo Pharma Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Redesca® and Redesca HP®

Tuesday, April 6, 2021 - 12:00pm

(CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca and Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, for the prevention and treatment of thromboembolic disorders.

Key Points: 
  • (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, today announced that it has completed its negotiations and entered into a letter of intent ("LOI") with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding Redesca and Redesca HP, its low molecular weight heparin ("LMWH") biosimilar, for the prevention and treatment of thromboembolic disorders.
  • "The successful conclusion of negotiations with pCPA is a significant milestone delivered for the Redesca commercialization program.
  • Redesca has more than 8 years of proven in-market safety internationally and more than 150 million patient days treated in Europe alone.
  • Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products.

LEO Foundation and Nordic Capital Partner up to Further Strengthen LEO Pharma’s Leading Position in Medical Dermatology

Tuesday, March 23, 2021 - 12:00pm

Nordic Capital, a leading global healthcare private equity investor, invests in LEO Pharma and becomes an active minority owner and partner to the LEO Foundation.

Key Points: 
  • Nordic Capital, a leading global healthcare private equity investor, invests in LEO Pharma and becomes an active minority owner and partner to the LEO Foundation.
  • View the full release here: https://www.businesswire.com/news/home/20210323005629/en/
    LEO Foundation and Nordic Capital Partner up to Further Strengthen LEO Pharmas Leading Position in Medical Dermatology (Photo: Business Wire)
    In 2020, LEO Pharma launched its 2030 strategy with the ambition to be a global leader in medical dermatology by expanding its leading branded topical dermatology franchise and developing a deep, innovative pipeline.
  • To support the companys long-term objectives and ambitious growth strategy, the LEO Foundation now welcomes Nordic Capital as a new active minority owner.
  • We could not be more pleased that Nordic Capital is partnering with the LEO Foundation and LEO Pharma, said Jonas Agnblad, Partner, Co-Head of Healthcare, Nordic Capital Advisors.

LEO Pharma Delivered on Strategic Ambitions and Showed Resilience During COVID-19 Pandemic in 2020

Tuesday, March 23, 2021 - 12:00pm

LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%)

Key Points: 
  • LEO Pharma net sales recovered from COVID-19 impact during the year, reaching DKK 10.1 billion (-6%)
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210323005618/en/
    LEO Pharma Delivered on Strategic Ambitions and Showed Resilience During COVID-19 Pandemic in 2020 (Photo: Business Wire)
    Strategic psoriasis products Enstilar and Kyntheum continued to grow and gain market share.
  • This was offset by the impact of coronavirus lockdowns, generics in Europe and further price pressure in the US.
  • Catherine Mazzacco, CEO and President of LEO Pharma commented:
    2020 was an eventful year for all, but I am happy to say that LEO Pharma delivered significant strategic progress and solid financial performance.

LEO Pharma Strengthens Global Leadership Team With Appointment of Jörg Möller as Executive Vice President, Global Research and Development

Wednesday, December 16, 2020 - 3:05pm

LEO Pharma A/S today announced that Jrg Mller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021.

Key Points: 
  • LEO Pharma A/S today announced that Jrg Mller will join its Global Leadership Team as Executive Vice President, Global Research and Development, effective January 1, 2021.
  • Mller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.
  • Jrg Mller succeeds Kim Kjller who, as previously announced, decided to leave LEO Pharma for a CEO role at Union Therapeutics.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.

LEO Pharma to Highlight New Data in Medical Dermatology at EADV Virtual 2020

Tuesday, October 27, 2020 - 12:22pm

For more information about LEO Pharma, visit https://www.leo-pharma.us or www.leo-pharma.com .

Key Points: 
  • For more information about LEO Pharma, visit https://www.leo-pharma.us or www.leo-pharma.com .
  • HE is considered chronic (CHE) when it lasts for more than three months or relapses twice or more per year.
  • Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions.
  • LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries.